Jade Biosciences Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for inflammation and immunology indications in patients with autoimmune diseases. Its lead candidate, JADE101, is a monoclonal antibody designed to inhibit the cytokine APRIL (A Proliferation-Inducing Ligand) and targets immunoglobulin A nephropathy (IgAN), a chronic kidney disease that damages kidney function by promoting harmful IgA antibodies and proteinuria. The company's pipeline also features JADE201, an anti-BAFF-R (B-cell activating factor receptor) program, and JADE301, an undisclosed antibody initiative, all aimed at creating potentially best-in-class, disease-modifying biologics. Jade Biosciences Inc. builds on discovery-stage assets licensed from Paragon Therapeutics to address critical unmet needs in autoimmune conditions. Incorporated in 2024 and headquartered in Waltham, Massachusetts, the company operates in the healthcare sector, advancing its programs through clinical trials including ongoing Phase 1 studies for JADE101 with planned Phase 2 initiation.